-
Among the 9 high-paying positions in the pharmaceutical industry, the fifth is a pharmaceutical representative...
Time of Update: 2022-01-01
This position needs to have a certain understanding of pharmaceutical policies and medicine, collect national drug administration information and policies, write application materials, organize and update drug research and development technology Guidance documents, sorting out company registration application materials, etc.
-
GlaxoSmithKline/Vir monoclonal antibody sotrovimab is effective against key Omicron mutations
Time of Update: 2022-01-01
Compile | newbornOn December 2, GlaxoSmithKline (GSK) and Vir Biotech announced an update of a study on the preprinted website bioRxiv: Preclinical data showed that the monoclonal antibody sotrovimab targets the new Omicron SARS-CoV-2 variant ( B.
-
Stuximab introduced by BeiGene is approved to be marketed in China for the treatment of multicenter Casterman's disease
Time of Update: 2022-01-01
On December 2, the State Food and Drug Administration issued an announcement stating that it has recently passed the priority review and approval procedure to approve the import registration application of Stuximab (English name: Siltuximab for Injection) for the injection of rare disease drugs in urgent need of clinical use for human immunization.
-
Novartis' next-generation IgE antibody application for clinical application has received FDA breakthrough therapy designation
Time of Update: 2022-01-01
In a phase IIb (NCT02477332) dose exploratory study of patients with moderate to severe CSU, compared with Novartis’s previous generation IgE antibody Xolair (omalizumab) group, more people in the ligelizumab group had complete remission of urticaria (51 % vs.
-
Naproxen Sodium Tablets, a subsidiary of Renfu Pharmaceutical Holdings, obtained the drug registration certificate
Time of Update: 2022-01-01
Yichang Renfu’s naproxen sodium tablets were approved by the FDA in August 2019, and the registration application for the drug was submitted to the National Medical Products Administration in November 2019 and was accepted.
-
Amgen postpones the launch of Samsung's Enbrel biosimilar to 2029
Time of Update: 2022-01-01
According to the latest judgment, Samsung Bioepis will not be able to manufacture, sell or import Enbrel biosimilar drugs in the United States before 2029 .
-
Well-known pharmaceutical company fined 32.07 million for adding extracts illegally
Time of Update: 2022-01-01
When Herentang Pharmaceutical produces the drug "Kangfuling Capsules", it illegally extracts the cork extract powder and adds it to ensure that the product content meets the standard requirements .
-
249 domestic pharmaceutical companies are listed in the "World's Top Thousands", and these 5 have outstanding performance
Time of Update: 2022-01-01
. A number of brokerage research reports believe that as Hengrui Pharmaceuticals continues to increase its international layout, it is expected to further expand the pipeline of innovative products and increase the company's performance in the future .
-
Domestic pharmaceutical companies have been rejected for listing new drugs, and innovative R&D is not easy
Time of Update: 2022-01-01
Recently, Wanchun Medicine issued an announcement stating that the marketing application of Pranabrin for the treatment of chemotherapy-induced neutropenia (CIN) has received a complete response letter (CRL) from the US FDA .
-
Industry Appeal: Incorporate online sales of drugs into the "Law Net" as soon as possible
Time of Update: 2022-01-01
. The author has learned that, in order to further regulate drug online sales activities and severely crack down on illegal drug online sales, many cities have already carried out special management work on drug online sales .
-
A pharmacy sells inferior drugs without fines of 100,000
Time of Update: 2022-01-01
Based on the above facts, in accordance with the relevant penal provisions of the "Regulations on the Implementation of the Drug Administration Law", the regulatory authorities impose the following penalties on pharmacies:Ordered to correct relevant illegal acts, and confiscated 55 yuan of illegal gains .
-
In 2022, the wave of layoffs among multinational pharmaceutical companies is expected to continue!
Time of Update: 2022-01-01
According to incomplete statistics in the industry, from January to November 2021, at least 28 multinational pharmaceutical companies have experienced layoffs, including Sanofi, Amgen, Gilead, Well-known large pharmaceutical companies such as Novartis, GlaxoSmithKline, Mylan, Gilead, Johnson & Johnson, and AstraZeneca .
-
Recently, there has been frequent cooperation between pharmaceutical companies in diagnosis
Time of Update: 2022-01-01
In addition, AstraZeneca also plans to apply the above-mentioned products developed in cooperation with Genetron Health to clinical trials involving customized solid tumor MRD detection in China .
-
The new year is approaching, and domestic and foreign pharmaceutical companies such as Novartis and Conba have dumped their assets!
Time of Update: 2022-01-01
through public listing in Zhejiang Equity Exchange; on September 23, the company announced that it intends to transfer its holdings of Jiangxi Zhenshiming Pharmaceutical Co.
-
A large number of pharmaceutical companies have unsatisfactory cross-border effects. How to solve the dilemma?
Time of Update: 2022-01-01
At present, in addition to North China Medicine, there are actually a large number of pharmaceutical companies in tea, daily necessities and other industries that are entering the market across the border .
-
China Resources Sanjiu Chairman Wang Chuncheng resigns
Time of Update: 2022-01-01
On December 4, China Resources Sanjiu issued an announcement stating that the company received a resignation report from the chairman of the board, Mr.
As of the date of this announcement, Wang Chuncheng does not hold the company's stock .
-
Recently, a number of pharmacies have been delisted from the market, and the industry concentration is accelerating
Time of Update: 2022-01-01
The Liaoning Provincial Announcement pointed out that, in accordance with relevant regulations, the bureau decided to cancel the Pharmaceutical Business License of Chaoyang Huaxing Pharmacy Chain Co.
-
After the listed chain made another move, another 81 pharmacies were acquired!
Time of Update: 2022-01-01
In addition to this acquisition, on April 14 this year, Jianzhijia issued an announcement stating that its wholly-owned subsidiary, Yunnan Jianzhijia Chain Health Pharmacy Co.
In addition, on July 1, Jianzhijia issued an announcement stating that it intends to acquire 100% equity of Pingguo Yujia Pharmaceutical Chain Co.
-
On the same day, two pharmaceutical companies announced that they would spend huge sums of money to build production projects
Time of Update: 2022-01-01
Haixiang Pharmaceutical intends to invest 2 billion yuan to build a comprehensive production base project in Hubei Pharmaceutical and Chemical Industry.
-
Lingkang Pharmaceutical obtained approval for drug registration with piperacillin sodium and sulbactam sodium for injection
Time of Update: 2022-01-01
. Piperacillin sodium and sulbactam sodium for injection (4:1) Indications: suitable for moderate to severe infections caused by β-lactamase-producing bacteria that are resistant to piperacillin and sensitive to this product.
